Takeda Pharmaceutical Company Limited

BOVESPA:TAKP34 Stock Report

Market Cap: R$248.3b

Takeda Pharmaceutical Future Growth

Future criteria checks 1/6

Takeda Pharmaceutical is forecast to grow earnings and revenue by 12.4% and 0.9% per annum respectively. EPS is expected to grow by 12% per annum. Return on equity is forecast to be 4.1% in 3 years.

Key information

12.4%

Earnings growth rate

12.0%

EPS growth rate

Pharmaceuticals earnings growth19.6%
Revenue growth rate0.9%
Future return on equity4.1%
Analyst coverage

Good

Last updated25 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BOVESPA:TAKP34 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20274,565,832291,493675,690974,75116
3/31/20264,506,961222,124687,713951,88717
3/31/20254,464,729108,675409,238820,63012
9/30/20244,546,083289,996536,390876,306N/A
6/30/20244,413,134149,920444,957794,248N/A
3/31/20244,263,762144,067235,614716,344N/A
12/31/20234,169,049178,219-129,035731,449N/A
9/30/20234,154,414191,626129,243963,227N/A
6/30/20234,113,631301,398180,765985,315N/A
3/31/20234,027,478317,017343,467977,156N/A
12/31/20223,944,611274,525817,6151,059,047N/A
9/30/20223,749,354213,167789,0891,028,328N/A
6/30/20223,591,868197,389798,3671,040,488N/A
3/31/20223,569,006230,059937,0681,123,105N/A
12/31/20213,465,991438,515902,3091,148,481N/A
9/30/20213,401,450473,105777,5721,018,931N/A
6/30/20213,345,565431,178793,6451,031,928N/A
3/31/20213,197,812376,005774,4631,010,931N/A
12/31/20203,199,240180,631608,015795,408N/A
9/30/20203,221,80456,051498,511720,676N/A
6/30/20203,243,917119,743479,618694,824N/A
3/31/20203,291,18844,241452,042669,752N/A
12/31/20193,236,69713,275402,421601,798N/A
9/30/20192,876,78283,262399,600551,732N/A
6/30/20192,496,51163,959266,965408,797N/A
3/31/20192,097,224135,192194,365328,479N/A
12/31/20181,780,976110,414221,992336,742N/A
9/30/20181,769,726140,738225,190328,658N/A
6/30/20181,772,125120,339N/A343,761N/A
3/31/20181,770,531186,886N/A377,854N/A
12/31/20171,785,773190,172N/A376,566N/A
9/30/20171,762,667163,457N/A316,619N/A
6/30/20171,746,286160,202N/A285,157N/A
3/31/20171,732,051114,940N/A261,363N/A
12/31/20161,729,967132,194N/A-8,176N/A
9/30/20161,754,130150,081N/A42,293N/A
6/30/20161,795,088155,110N/A57,618N/A
3/31/20161,807,37880,166N/A25,491N/A
12/31/20151,831,096-111,874N/A203,553N/A
9/30/20151,830,521-152,827N/A192,836N/A
6/30/20151,812,971-154,591N/A189,123N/A
3/31/20151,777,824-145,775N/A182,517N/A
12/31/20141,744,79575,405N/AN/AN/A
9/30/20141,714,694103,390N/A240,094N/A
6/30/20141,692,531110,981N/AN/AN/A
3/31/20141,691,685106,658N/A148,335N/A
12/31/20131,655,033103,330N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TAKP34's forecast earnings growth (12.4% per year) is above the savings rate (10.4%).

Earnings vs Market: TAKP34's earnings (12.4% per year) are forecast to grow slower than the BR market (12.6% per year).

High Growth Earnings: TAKP34's earnings are forecast to grow, but not significantly.

Revenue vs Market: TAKP34's revenue (0.9% per year) is forecast to grow slower than the BR market (7.4% per year).

High Growth Revenue: TAKP34's revenue (0.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TAKP34's Return on Equity is forecast to be low in 3 years time (4.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y